Sophie Visvikis-Siest

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1487561/publications.pdf

Version: 2024-02-01

290 papers 34,390 citations

59 h-index 176 g-index

313 all docs 313 does citations

313 times ranked 51587 citing authors

#	Article	IF	CITATIONS
1	Integrating polymorphism signatures with myocardial perfusion imaging data to improve the prevention of coronary artery disease: Science or science-fiction?. Journal of Nuclear Cardiology, 2022, 29, 2917-2919.	2.1	O
2	The association of vascular endothelial growth factor related SNPs and circulating iron levels might depend on body mass index. Frontiers in Bioscience, 2022, 27, 1.	2.1	1
3	Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. International Journal of Environmental Research and Public Health, 2022, 19, 971.	2.6	2
4	VEGF-A-related genetic variants protect against Alzheimer's disease. Aging, 2022, 14, 2524-2536.	3.1	10
5	Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 2021, 12, 24.	12.8	87
6	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	2.9	32
7	Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. ELife, $2021,10,10$	6.0	41
8	Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. Molecular Nutrition and Food Research, 2021, 65, e2001178.	3.3	19
9	Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD. Frontiers in Immunology, 2021, 12, 683028.	4.8	12
10	Epigenome-wide association study detects a novel loci associated with central obesity in healthy subjects. BMC Medical Genomics, 2021, 14, 233.	1.5	3
11	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, The, 2021, 398, 957-980.	13.7	1,289
12	Dietary Patterns, Blood Pressure and the Glycemic and Lipidemic Profile of Two Teenage, European Populations. Nutrients, 2021, 13, 198.	4.1	6
13	A genetic determinant of VEGF-A levels is associated with telomere attrition. Aging, 2021, 13, 23517-23526.	3.1	2
14	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	1.9	44
15	Telomere length determinants in childhood. Clinical Chemistry and Laboratory Medicine, 2020, 58, 162-177.	2.3	33
16	Milestones in Personalized Medicine: From the Ancient Time to Nowadaysâ€"the Provocation of COVID-19. Frontiers in Genetics, 2020, 11, 569175.	2.3	17
17	Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. Lancet, The, 2020, 396, 1511-1524.	13.7	219
18	Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020, 582, 73-77.	27.8	138

#	Article	IF	Citations
19	Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration. Clinical Epigenetics, 2020, 12, 79.	4.1	4
20	Increased risk of hypercholesterolemia in a French and Lebanese population due to an interaction between rs2569190 in CD14 and gender. Clinica Chimica Acta, 2020, 509, 172-176.	1.1	1
21	TERC Variants Associated with Short Leukocyte Telomeres: Implication of Higher Early Life Leukocyte Telomere Attrition as Assessed by the Blood-and-Muscle Model. Cells, 2020, 9, 1360.	4.1	3
22	Obesity status modifies the association between rs7556897T>C in the intergenic region SLC19A3-CCL20 and blood pressure in French children. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1819-1827.	2.3	3
23	Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population. PLoS ONE, 2019, 14, e0220902.	2.5	7
24	Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature, 2019, 569, 260-264.	27.8	469
25	Genetic determinants of circulating haptoglobin concentration. Clinica Chimica Acta, 2019, 494, 138-142.	1.1	14
26	Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS). International Journal of Molecular Sciences, 2019, 20, 1014.	4.1	17
27	Do we need diagnostic strategies enhanced with genetic information for ischemic heart disease?. Journal of Nuclear Cardiology, 2019, 26, 1309-1312.	2.1	1
28	Pleiotropy of ABO gene: correlation of rs644234 with E-selectin and lipid levels. Clinical Chemistry and Laboratory Medicine, 2018, 56, 748-754.	2.3	8
29	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal of Epidemiology, 2018, 47, 872-883i.	1.9	65
30	The Relationship Between Vascular Endothelial Growth Factor Cis- and Trans-Acting Genetic Variants and Metabolic Syndrome. American Journal of the Medical Sciences, 2018, 355, 559-565.	1.1	8
31	Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metabolism and Personalized Therapy, 2018, 33, 41-47.	0.6	5
32	Effect of <i>LSR</i> polymorphism on blood lipid levels and ageâ€specific epistatic interaction with the <i>APOE</i> common polymorphism. Clinical Genetics, 2018, 93, 846-852.	2.0	5
33	A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Clinical Chemistry and Laboratory Medicine, 2018, 56, 83-86.	2.3	1
34	VEGF-A is associated with early degenerative changes in cartilage and subchondral bone. Growth Factors, 2018, 36, 263-273.	1.7	14
35	Personalised Medicine: The Odyssey from Hope to Practice. Journal of Personalized Medicine, 2018, 8, 31.	2.5	9
36	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	6.2	326

#	Article	IF	CITATIONS
37	The future of telomere length in personalized medicine. Frontiers in Bioscience - Landmark, 2018, 23, 1628-1654.	3.0	33
38	The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-1± levels and IMT-F. Scientific Reports, 2018, 8, 7160.	3.3	3
39	Epistatic interaction of apolipoprotein E and lipolysis-stimulated lipoprotein receptor genetic variants is associated with Alzheimer's disease. Neurobiology of Aging, 2018, 69, 292.e1-292.e5.	3.1	4
40	VEGF-related polymorphisms identified by GWAS and risk for major depression. Translational Psychiatry, 2017, 7, e1055-e1055.	4.8	34
41	VEGF, the underlying factor for metabolic syndrome; fact or fiction?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S61-S64.	3.6	30
42	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet, The, 2017, 390, 2627-2642.	13.7	5,010
43	Next generation sequencing and immuno-histochemistry profiling identify numerous biomarkers for personalized therapy of endometrioid endometrial carcinoma. Clinical Chemistry and Laboratory Medicine, 2017, 56, e19-e22.	2.3	1
44	IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP, LDL and ApoB levels. Genes and Immunity, 2017, 18, 163-169.	4.1	7
45	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with $19 \text{\^A} \cdot 1$ million participants. Lancet, The, 2017, 389, 37-55.	13.7	1,667
46	Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice. Current Pharmaceutical Biotechnology, 2017, 18, 231-241.	1.6	8
47	TREM-1 SNP rs2234246 regulates TREM-1 protein and mRNA levels and is associated with plasma levels of L-selectin. PLoS ONE, 2017, 12, e0182226.	2.5	31
48	Cardiovascular diseases-related GNB3 C825T polymorphism has a significant sex-specific effect on serum soluble E-selectin levels. Journal of Inflammation, 2016, 13, 39.	3.4	5
49	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet, The, 2016, 387, 1513-1530.	13.7	2,842
50	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with $19\hat{A}\cdot2$ million participants. Lancet, The, 2016, 387, 1377-1396.	13.7	3,941
51	Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. Autoimmunity, 2016, 49, 366-372.	2.6	6
52	Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases. Autoimmunity, 2016, 49, 229-235.	2.6	6
53	Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies. PLoS Genetics, 2016, 12, e1005874.	3.5	56
54	De l'écogénétique à la pharmacogénomique par le stress oxydant. HEGEL - HEpato-GastroEntérol Libérale, 2016, N° 2, 217a-218.	ogje O.O	0

#	Article	IF	CITATIONS
55	Le Professeur Gérard Siest nous a quittés (1936-2016). HEGEL - HEpato-GastroEntérologie Libérale, 2010 N° 2, 96-97.	6, ₀ .0	O
56	Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Medical Genetics, 2015, 16, 90.	2.1	27
57	Beyond genome-wide association studies: identifying variants using -omics approaches. Personalized Medicine, 2015, 12, 529-531.	1.5	0
58	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331â€^288 participants. Lancet Diabetes and Endocrinology,the, 2015, 3, 624-637.	11.4	139
59	Genetic Determinants of Leucocyte Telomere Length in Children: a Neglected and Challenging Field. Paediatric and Perinatal Epidemiology, 2015, 29, 146-150.	1.7	10
60	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. Pharmacogenomics, 2015, 16, 459-469.	1.3	0
61	Public Biobanks: Calculation and Recovery of Costs. Science Translational Medicine, 2014, 6, 261fs45.	12.4	47
62	Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics, 2014, 15, 739-744.	1.3	1
63	Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Drug Metabolism Reviews, 2014, 46, 33-56.	3.6	24
64	Low copy number of the salivary amylase gene predisposes to obesity. Nature Genetics, 2014, 46, 492-497.	21.4	214
65	Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders. , 2014, 144, 134-161.		74
66	Epistatic study reveals two genetic interactions in blood pressure regulation. BMC Medical Genetics, 2013, 14, 2.	2.1	13
67	Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine, 2013, 61, 602-607.	3.2	24
68	Dairy product consumption, calcium intakes, and metabolic syndromeâ€"related factors over 5 years in the STANISLAS study. Nutrition, 2013, 29, 519-524.	2.4	60
69	Relationship between catalase haplotype and arterial aging. Atherosclerosis, 2013, 227, 100-105.	0.8	14
70	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. International Journal of Cardiology, 2013, 168, 3057-3058.	1.7	2
71	A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. Journal of Lipid Research, 2013, 54, 535-541.	4.2	28
72	Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. PLoS Medicine, 2013, 10, e1001383.	8.4	753

#	Article	IF	Citations
73	Mining the Human Phenome Using Allelic Scores That Index Biological Intermediates. PLoS Genetics, 2013, 9, e1003919.	3.5	84
74	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 16402-16413.	4.1	1
75	What Is the Contribution of Two Genetic Variants Regulating VEGF Levels to Type 2 Diabetes Risk and to Microvascular Complications?. PLoS ONE, 2013, 8, e55921.	2.5	35
76	Association of TERC and OBFC1 Haplotypes with Mean Leukocyte Telomere Length and Risk for Coronary Heart Disease. PLoS ONE, 2013, 8, e83122.	2.5	42
77	Genome-Wide Association for Abdominal Subcutaneous and Visceral Adipose Reveals a Novel Locus for Visceral Fat in Women. PLoS Genetics, 2012, 8, e1002695.	3.5	245
78	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genetics, 2012, 8, e1002607.	3.5	419
79	Common mutations and polymorphisms predicting adverse cardiovascular events: current view. Pharmacogenomics, 2012, 13, 1875-1878.	1.3	1
80	Influence of Pre-analytical Variables on VEGF Gene Expression and Circulating Protein Concentrations. Biopreservation and Biobanking, 2012, 10, 454-461.	1.0	15
81	Novel association approach for variable number tandem repeats (VNTRs) identifies DOCK5 as a susceptibility gene for severe obesity. Human Molecular Genetics, 2012, 21, 3727-3738.	2.9	37
82	Alcohol Consumption, Beverage Preference, and Diet in Middle-Aged Men from the STANISLAS Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-6.	1.8	21
83	Need for pharmacogenomic information also for generic medications: Recommendation of the European Society of Pharmacogenomics and Theranostics (ESPT). Drug Metabolism and Drug Interactions, 2012, 27, 119.	0.3	0
84	Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Human Molecular Genetics, 2012, 21, 5385-5394.	2.9	210
85	Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. Pharmacogenomics, 2012, 13, 1215-1218.	1.3	5
86	Genetic biomarkers of hypertension and future challenges integrating epigenomics. Clinica Chimica Acta, 2012, 414, 259-265.	1.1	32
87	Human formyl peptide receptor 1 C32T SNP interacts with age and is associated with blood pressure levels. Clinica Chimica Acta, 2012, 413, 34-38.	1.1	15
88	Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999. Clinica Chimica Acta, 2012, 413, 1618-1624.	1.1	15
89	High Prevalence of Metabolic Syndrome in Iran in Comparison with France: What Are the Components That Explain This?. Metabolic Syndrome and Related Disorders, 2012, 10, 181-188.	1.3	51
90	A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans. PLoS ONE, 2012, 7, e29202.	2.5	197

#	Article	IF	Citations
91	A Genome-Wide Association Study Identifies rs2000999 as a Strong Genetic Determinant of Circulating Haptoglobin Levels. PLoS ONE, 2012, 7, e32327.	2.5	34
92	Functional Epistatic Interaction between rs6046G>A in F7 and rs5355C>T in SELE Modifies Systolic Blood Pressure Levels. PLoS ONE, 2012, 7, e40777.	2.5	8
93	Functional genomics towards personalized healthcare and systems medicine. Personalized Medicine, 2011, 8, 227-242.	1.5	1
94	Childhood Obesity Is Associated with Shorter Leukocyte Telomere Length. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1500-1505.	3.6	127
95	Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature, 2011, 478, 97-102.	27.8	394
96	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	21.4	501
97	Klotho KL-VS genotype is involved in blood pressure regulation. Clinica Chimica Acta, 2011, 412, 1773-1777.	1.1	19
98	Cardiovascular diseases and genome-wide association studies. Clinica Chimica Acta, 2011, 412, 1697-1701.	1.1	22
99	The Lin28/let-7 Axis Regulates Glucose Metabolism. Cell, 2011, 147, 81-94.	28.9	812
100	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
101	Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genetics, 2011, 7, e1001324.	3.5	796
102	Substantial variation in qPCR measured mean blood telomere lengths in young men from eleven European countries. American Journal of Human Biology, 2011, 23, 228-231.	1.6	37
103	Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy. Pharmacogenomics, 2011, 12, 681-691.	1.3	4
104	Identification of <i>cis</i> - and <i>trans</i> -Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels. Circulation Research, 2011, 109, 554-563.	4.5	72
105	Association of Genetic Loci With Glucose Levels in Childhood and Adolescence. Diabetes, 2011, 60, 1805-1812.	0.6	103
106	Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort. Drug Metabolism and Drug Interactions, 2011, 26, 27-32.	0.3	3
107	Association Between Angiotensin II Type 1 Receptor Gene Polymorphism andÂMetabolic Syndrome in a Young Female Iranian Population. Archives of Medical Research, 2010, 41, 343-349.	3.3	17
108	A multiâ€stage multiâ€design strategy provides strong evidence that the BAI3 locus is associated with earlyâ€onset venous thromboembolism. Journal of Thrombosis and Haemostasis, 2010, 8, 2671-2679.	3.8	42

#	Article	IF	Citations
109	Expression of inflammatory molecules and associations with BMI in children. European Journal of Clinical Investigation, 2010, 40, 388-392.	3.4	23
110	Sexâ€dependent Associations of Leptin With Metabolic Syndrome–related Variables: The Stanislas Study. Obesity, 2010, 18, 196-201.	3.0	24
111	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	21.4	2,634
112	Prevalence of Loss-of-Function FTO Mutations in Lean and Obese Individuals. Diabetes, 2010, 59, 311-318.	0.6	93
113	Interactions of Dietary Whole-Grain Intake With Fasting Glucose- and Insulin-Related Genetic Loci in Individuals of European Descent: A meta-analysis of 14 cohort studies. Diabetes Care, 2010, 33, 2684-2691.	8.6	127
114	Association Study of Gene Polymorphisms Involved in Vascular Alterations in Elderly Hypertensives with Subjective Memory Complaints. Dementia and Geriatric Cognitive Disorders, 2010, 30, 440-448.	1.5	11
115	Metabolic syndrome-related composite factors over 5 years in the STANISLAS Family Study: Genetic heritability and common environmental influences. Clinica Chimica Acta, 2010, 411, 833-839.	1.1	14
116	MS64 CAPILLARY ISOTACHOPHORESIS AS AN OVERALL TOOL TO REVEAL ATHEROGENIC LIPOPROTEIN PHENOTYPE. Atherosclerosis Supplements, 2010, 11, 123.	1.2	0
117	New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics, 2010, 42, 105-116.	21.4	1,982
118	Visfatin: The Link Between Inflammation and Childhood Obesity. Diabetes Care, 2009, 32, e71-e71.	8.6	20
119	Personalized therapy and pharmacogenomics: future perspective. Pharmacogenomics, 2009, 10, 927-930.	1.3	9
120	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 2. ApoE and apoC-III relations in triglyceride clearance. Molecular and Cellular Biochemistry, 2009, 325, 25-40.	3.1	3
121	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins. Molecular and Cellular Biochemistry, 2009, 325, 41-51.	3.1	3
122	Genetic profiling of human cell lines used as in vitro model to study cardiovascular pathophysiology and pharmacotoxicology. Cell Biology and Toxicology, 2009, 25, 561-571.	5.3	6
123	A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nature Genetics, 2009, 41, 89-94.	21.4	540
124	Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nature Genetics, 2009, 41, 157-159.	21.4	585
125	Association between EGF and lipid concentrations: A benefit role in the atherosclerotic process?. Clinica Chimica Acta, 2009, 402, 196-198.	1.1	8
126	Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clinica Chimica Acta, 2009, 403, 198-202.	1,1	23

#	Article	IF	Citations
127	Adipokine expression in adipose tissue and in peripheral blood mononuclear cells in children. Clinica Chimica Acta, 2009, 410, 85-89.	1.1	7
128	Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 720-728.	2.6	28
129	Human formyl peptide receptor 1 (<i>FPR1</i>) c.32C>T SNP is associated with decreased soluble E-selectin levels. Pharmacogenomics, 2009, 10, 951-959.	1.3	8
130	Parental precocious influences on offspring cardiovascular risk markers: an exploratory study in the STANISLAS Cohort. Personalized Medicine, 2009, 6, 343-352.	1.5	0
131	Candidate gene microarray analysis in peripheral blood cells for studying hypertension/obesity. Personalized Medicine, 2009, 6, 269-291.	1.5	5
132	Functional genomics towards personalized healthcare. Personalized Medicine, 2009, 6, 19-32.	1.5	3
133	Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps. Current Drug Metabolism, 2009, 10, 410-419.	1.2	5
134	Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases. Current Pharmaceutical Design, 2009, 15, 3193-3206.	1.9	12
135	The association of telomere length with paternal history of premature myocardial infarction in the European Atherosclerosis Research Study II. Journal of Molecular Medicine, 2008, 86, 815-824.	3.9	54
136	Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the Stanislas study. International Journal of Obesity, 2008, 32, 1279-1288.	3.4	27
137	Genetic Polymorphism of <i>CYP2C19</i> Gene in the Stanislas Cohort. A link with Inflammation. Annals of Human Genetics, 2008, 72, 178-183.	0.8	35
138	P-selectin polymorphisms' influences on P-selectin serum concentrations and on their familial correlation: the STANISLAS family study. Journal of Thrombosis and Haemostasis, 2008, 6, 920-927.	3.8	9
139	Visfatin, lowâ€grade inflammation and body mass index (BMI). Clinical Endocrinology, 2008, 69, 568-574.	2.4	38
140	Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: Review and hypothesis. Vascular Pharmacology, 2008, 48, 70-75.	2.1	10
141	Pharmacogenomics and Cardiovascular Drugs. Methods in Pharmacology and Toxicology, 2008, , 413-446.	0.2	0
142	Leptin expression in Peripheral Blood Mononuclear Cells (PBMCs) is related with blood pressure variability. Clinica Chimica Acta, 2008, 395, 47-50.	1.1	15
143	Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects. Drug Metabolism and Disposition, 2008, 36, 182-189.	3.3	80
144	A new single nucleotide polymorphism genotyping method based on gap ligase chain reaction and a microsphere detection assay. Clinical Chemistry and Laboratory Medicine, 2008, 46, 486-9.	2.3	4

#	Article	IF	Citations
145	The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clinical Chemistry and Laboratory Medicine, 2008, 46, 733-47.	2.3	50
146	Genetic profiling in healthy subjects from the Stanislas cohort based on 24 polymorphisms: effects on biological variables. Clinical Chemistry and Laboratory Medicine, 2008, 46, 64-72.	2.3	1
147	Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1339-46.	2.3	11
148	Effect of HMGCoA Reductase Inhibitors on Cytochrome P450 Expression in Endothelial Cell Line. Journal of Cardiovascular Pharmacology, 2007, 49, 306-315.	1.9	23
149	Enzymes and pharmacogenetics of cardiovascular drugs. Clinica Chimica Acta, 2007, 381, 26-31.	1.1	40
150	Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. Atherosclerosis, 2007, 191, 369-376.	0.8	13
151	Association between TNF and IL-1 bloc polymorphisms and plasma MCP-1 concentration. Atherosclerosis, 2007, 192, 348-353.	0.8	11
152	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Personalized Medicine, 2007, 4, 393-412.	1.5	4
153	The Lipoprotein Lipase Serine 447 Stop Polymorphism Is Associated With Altered Serum Carotenoid Concentrations in the Stanislas Family Study. Journal of the American College of Nutrition, 2007, 26, 655-662.	1.8	29
154	Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1154-68.	2.3	55
155	From human genetic variations to prediction of risks and responses to drugs and the environment. Personalized Medicine, 2007, 4, 95-104.	1.5	3
156	Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles. Genes and Immunity, 2007, 8, 352-359.	4.1	10
157	Lack of Association between EGF 61A>G Polymorphism and Plasma EGF Concentration in the STANISLAS Family Study. Journal of Investigative Dermatology, 2007, 127, 969-970.	0.7	3
158	Heritability for Plasma VEGF Concentration in the Stanislas Family Study. Annals of Human Genetics, 2007, 71, 54-63.	0.8	33
159	Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundamental and Clinical Pharmacology, 2007, 21, 411-418.	1.9	40
160	Compared Effect of Immunosuppressive Drugs Cyclosporine A and Rapamycin on Cholesterol Homeostasis Key Enzymes CYP27A1 and HMG-CoA Reductase. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 392-397.	2.5	37
161	Th-P15:66 Changes in lipid and apolipoprotein E distribution induced by lipoprotein lipolysis in vivo in hypertriglyceridemia. Atherosclerosis Supplements, 2006, 7, 507.	1.2	0
162	Genetic and environmental contributions to serum ascorbic acid concentrations: the Stanislas Family Study. British Journal of Nutrition, 2006, 96, 1013-1020.	2.3	2

#	Article	IF	Citations
163	Interaction between CYP1A1 T3801C and AHR G1661A polymorphisms according to smoking status on blood pressure in the Stanislas cohort. Journal of Hypertension, 2006, 24, 2199-2205.	0.5	21
164	Genetic variants predisposing to cardiovascular disease. Current Opinion in Lipidology, 2006, 17, 139-151.	2.7	46
165	Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2006, 20, 98-104.	2.1	12
166	Biological Determinants of and Reference Values for Plasma Interleukin-8, Monocyte Chemoattractant Protein-1, Epidermal Growth Factor, and Vascular Endothelial Growth Factor: Results from the STANISLAS Cohort. Clinical Chemistry, 2006, 52, 504-510.	3.2	55
167	Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia. Clinical Chemistry and Laboratory Medicine, 2006, 44, 799-806.	2.3	3
168	Different Genes and Polymorphisms Affecting High-Density Lipoprotein Cholesterol Levels in Greek Familial Hypercholesterolemia Patients. Genetic Testing and Molecular Biomarkers, 2006, 10, 192-199.	1.7	10
169	Genetic determinants of blood pressure regulation. Journal of Hypertension, 2005, 23, 2127-2143.	0.5	94
170	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. British Journal of Haematology, 2005, 128, 91-99.	2.5	80
171	Eâ€Selectin Genotypes and Risk of Type 2 Diabetes in Women: Genetic and Environmental Contributions to Serum Soluble Eâ€Selectin Concentrations. Obesity, 2005, 13, 1845-1847.	4.0	5
172	Biological variations, genetic polymorphisms and familial resemblance of TNF- $\hat{l}\pm$ and IL-6 concentrations: STANISLAS cohort. European Journal of Human Genetics, 2005, 13, 109-117.	2.8	70
173	Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics Journal, 2005, 5, 271-275.	2.0	35
174	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology, 2005, 527, 1-22.	3.5	32
175	Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clinical and Experimental Medicine, 2005, 5, 196-201.	3.6	18
176	Polymorphism of the 5-HT2A receptor gene and food intakes in children and adolescents: the Stanislas Family Study. American Journal of Clinical Nutrition, 2005, 82, 467-470.	4.7	30
177	The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype. Biological Chemistry, 2005, 386, 441-52.	2.5	11
178	A Prospective Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: Two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-Â) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care, 2005, 28, 675-682.	8.6	32
179	Collection and Storage of Human Blood Cells for mRNA Expression Profiling: A 15-Month Stability Study. Clinical Chemistry, 2005, 51, 1250-1252.	3.2	37
180	Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese. Clinical Chemistry and Laboratory Medicine, 2005, 43, 817-22.	2.3	6

#	Article	IF	Citations
181	Inter-individual variation of inflammatory markers of cardiovascular risks and diseases. Clinical Chemistry and Laboratory Medicine, 2005, 43, 671-84.	2.3	17
182	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 862-8.	2.3	3
183	Effect of acute and chronic psychostimulant drugs on redox status, AP-1 activation and pro-enkephalin mRNA in the human astrocyte-like U373 MG cells. Neuropharmacology, 2005, 48, 673-684.	4.1	12
184	Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells. Toxicology Letters, 2005, 159, 203-211.	0.8	25
185	Association Between Factor VII Polymorphisms and Blood Pressure. Hypertension, 2004, 44, 674-680.	2.7	8
186	Age- and sex-related reference values for serum insulin concentration and its biological determinants in a French healthy population. The STANISLAS cohort. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1140-9.	2.3	12
187	Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics, 2004, 5, 779-802.	1.3	32
188	CYTOCHROMES P450 ARE DIFFERENTLY EXPRESSED IN NORMAL AND VARICOSE HUMAN SAPHENOUS VEINS: LINKAGE WITH VARICOSIS. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 295-301.	1.9	17
189	Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors. British Journal of Haematology, 2004, 126, 392-397.	2.5	7
190	Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases. Genomics, 2004, 83, 559-565.	2.9	26
191	M.581 The LEU554PHE polymorphism in the E-selectin gene is associated with blood pressure in overweight people. Atherosclerosis Supplements, 2004, 5, 135.	1.2	0
192	Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis, 2004, 172, 299-308.	0.8	78
193	The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. Journal of Hypertension, 2004, 22, 305-311.	0.5	27
194	Genetic influences on blood pressure within the Stanislas Cohort. Journal of Hypertension, 2004, 22, 297-304.	0.5	8
195	Synthesis and in Vitro Antioxidant Activity of Glycyrrhetinic Acid Derivatives Tested with the Cytochrome P450/NADPH System. Chemical and Pharmaceutical Bulletin, 2004, 52, 1436-1439.	1.3	28
196	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vascular Pharmacology, 2003, 40, 237-245.	2.1	6
197	Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2003, 59, 1127-1137.	3.9	9
198	Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort. European Journal of Human Genetics, 2003, 11, 679-686.	2.8	35

#	Article	IF	CITATIONS
199	Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis, 2003, 167, 223-230.	0.8	42
200	IL-6, TNF- \hat{l}_{\pm} and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis, 2003, 170, 277-283.	0.8	137
201	Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neuroscience Letters, 2003, 349, 95-98.	2.1	35
202	Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachophoresis study. International Journal of Biochemistry and Cell Biology, 2003, 35, 530-543.	2.8	10
203	Changes in Serum Retinol, α-Tocopherol, Vitamin C, Carotenoids, Zinc and Selenium after Micronutrient Supplementation during Alcohol Rehabilitation. Journal of the American College of Nutrition, 2003, 22, 303-310.	1.8	33
204	Effect of six candidate genes on early aging in a French population. Aging Clinical and Experimental Research, 2003, 15, 111-116.	2.9	14
205	Age- and Sex-related Reference Values for Serum Adhesion Molecule Concentrations in Healthy Individuals: Intercellular Adhesion Molecule-1 and E-, P-, and L-Selectin. Clinical Chemistry, 2003, 49, 1544-1546.	3.2	23
206	Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. Journal of Lipid Research, 2003, 44, 430-436.	4.2	27
207	Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?. Clinical Chemistry and Laboratory Medicine, 2003, 41, 554-8.	2.3	0
208	Pharmacogenomics of Drugs Affecting the Cardiovascular System. Clinical Chemistry and Laboratory Medicine, 2003, 41, 590-9.	2.3	14
209	Family study of the relationship between height and cardiovascular risk factors in the STANISLAS cohort. International Journal of Epidemiology, 2003, 32, 607-614.	1.9	22
210	Serum Total Antioxidant Status, Erythrocyte Superoxide Dismutase and Whole-Blood Glutathione Peroxidase Activities in the Stanislas Cohort: Influencing Factors and Reference Intervals. Clinical Chemistry and Laboratory Medicine, 2003, 41, 209-15.	2.3	33
211	PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study. Clinical Chemistry and Laboratory Medicine, 2003, 41, 535-40.	2.3	25
212	Molecular Pharmacophore Determination of Lipid Lowering Drugs with the Receptor Mapping Method. Mini-Reviews in Medicinal Chemistry, 2002, 2, 97-102.	2.4	2
213	Growing Significance of Myeloperoxidase in Non-infectious Diseases. Clinical Chemistry and Laboratory Medicine, 2002, 40, 2-8.	2.3	78
214	Apolipoprotein E Activates Akt Pathway in Neuro-2a in an Isoform-Specific Manner. Biochemical and Biophysical Research Communications, 2002, 292, 83-87.	2.1	28
215	Rapid spectrophotometric method for serum glutathione S-transferases activity. Clinica Chimica Acta, 2002, 326, 131-142.	1.1	81
216	Apolipoprotein E in Apolipoprotein B (apo B)- and Non-apo B-containing Lipoproteins in 3523 Participants in the Stanislas Cohort: Biological Variation and Genotype-specific Reference Limits. Clinical Chemistry, 2002, 48, 291-300.	3.2	10

#	Article	IF	Citations
217	Human Apolipoprotein E concentration in response to diseases and therapeutic treatments. Drug Development Research, 2002, 56, 95-110.	2.9	4
218	Extension of variance components approach to incorporate temporal trends and longitudinal pedigree data analysis. Genetic Epidemiology, 2002, 22, 221-232.	1.3	40
219	High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity. European Journal of Human Genetics, 2002, 10, 553-561.	2.8	75
220	The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. European Journal of Human Genetics, 2002, 10, 841-850.	2.8	75
221	Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. European Journal of Human Genetics, 2002, 10, 715-723.	2.8	67
222	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. Alcoholism: Clinical and Experimental Research, 2002, 26, 501-508.	2.4	7
223	Apolipoproteins E and C-III in apo B- and non-apo B-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and common apolipoprotein E polymorphism. Atherosclerosis, 2001, 155, 509-516.	0.8	12
224	<i>LEP</i> R gene polymorphisms: associations with overweight, fat mass and response to diet in women. European Journal of Clinical Investigation, 2001, 31, 398-404.	3.4	79
225	Sample size calculations for classical association and TDT-type methods using family data. Annals of Human Genetics, 2001, 65, 293-312.	0.8	3
226	Environmental And Genetic Determinants Of Intima-Media Thickness Of The Carotid Artery. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1007-1010.	1.9	13
227	APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas Cohort). Clinical Genetics, 2001, 59, 316-324.	2.0	29
228	Protein–lipid interactions in reconstituted high density lipoproteins: apolipoprotein and cholesterol influence. Chemistry and Physics of Lipids, 2001, 113, 67-82.	3.2	11
229	Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. European Journal of Human Genetics, 2001, 9, 780-786.	2.8	86
230	Candidate Gene Polymorphism in Cardiovascular Disease: A Comparative Study of Frequencies between a French and an Italian Population. Clinical Chemistry and Laboratory Medicine, 2001, 39, 146-54.	2.3	14
231	Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. Journal of Hypertension, 2000, 18, 1775-1781.	0.5	24
232	Familial Studies on the Genetics of Cardiovascular Diseases: the Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 2000, 38, 827-32.	2.3	15
233	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. Clinical Chemistry and Laboratory Medicine, 2000, 38, 721-730.	2.3	70
234	Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses. Clinical Chemistry and Laboratory Medicine, 2000, 38, 841-852.	2.3	58

#	Article	IF	CITATIONS
235	Genetic and Environmental Influences on Left Ventricular Mass. Hypertension, 2000, 36, 740-746.	2.7	48
236	Associations of Apolipoprotein E Concentration and Polymorphism with Lipids and Apolipoprotein Levels in Chinese from Beijing and Shanghai. Clinical Chemistry and Laboratory Medicine, 2000, 38, 655-9.	2.3	11
237	Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's diseaseâ~†. Neurobiology of Aging, 2000, 21, 27-30.	3.1	217
238	Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 14-28.	2.4	19
239	Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 29-40.	2.4	11
240	Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis, 2000, 152, 475-488.	0.8	132
241	Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Human Genetics, 2000, 107, 58-61.	3 . 8	6
242	Capillary electrophoretic analysis of recombinant human apolipoprotein E. Journal of Chromatography A, 1999, 853, 237-241.	3.7	7
243	Multilocus approach to cardiovascular risk. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 168-176.	1.2	6
244	A Parametric Copula Model for Analysis of Familial Binary Data. American Journal of Human Genetics, 1999, 64, 886-893.	6.2	22
245	Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: the EARS II study. Atherosclerosis, 1999, 145, 381-388.	0.8	42
246	A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk. Genome Research, 1999, 9, 936-949.	5. 5	193
247	A Comparison of Lifestyle, Genetic, Bioclinical and Biochemical Variables of Offspring with and without Family Histories of Premature Coronary Heart Disease: The Experience of the European Atherosclerosis Research Studies. European Journal of Cardiovascular Prevention and Rehabilitation, 1999, 6, 183-188.	2.8	15
248	Genetics strongly determines the wall thickness of the left and right carotid arteries. Human Genetics, 1998, 103, 183-188.	3.8	97
249	Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neuroscience Letters, 1998, 242, 117-119.	2.1	17
250	Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Letters, 1998, 425, 225-228.	2.8	97
251	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis, 1998, 140, 89-95.	0.8	51
252	Association of Apolipoprotein E Polymorphism and Concentration with Serum Lipids and Apo-lipoprotein Level in the Chinese from Shanghai. Clinical Chemistry and Laboratory Medicine, 1998, 36, 615-619.	2.3	10

#	Article	IF	CITATIONS
253	Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 84-91.	2.4	123
254	Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 1998, 36, 35-42.	2.3	130
255	DNA Extraction and Stability for Epidemiological Studies. Clinical Chemistry and Laboratory Medicine, 1998, 36, 551-5.	2.3	46
256	A Multilocus Genotyping Assay for Cardiovascular Disease. Clinical Chemistry and Laboratory Medicine, 1998, 36, 561-6.	2.3	45
257	Intima–media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort. Journal of Hypertension, 1998, 16, 1593-1602.	0.5	170
258	Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clinical Chemistry, 1998, 44, 957-965.	3.2	70
259	Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's Patients. Journal of Neurochemistry, 1998, 71, 1643-1650.	3.9	154
260	Apolipoprotein E Level in Cerebrospinal Fluid Increases With Aging. Journal of the American Geriatrics Society, 1997, 45, 1536-1536.	2.6	4
261	4.P.391 Familial study of genetic determinants of carotid intima-media thickness in an healthy population. Implication of apolipoprotein E polymorphism. Atherosclerosis, 1997, 134, 379.	0.8	0
262	4.P.232 Possible competition between VLDL and LDL for the binding to LDL receptor at hypertriglyceridemia - an in vitro estimate. Atherosclerosis, 1997, 134, 344.	0.8	0
263	1.P.326 Effect of apoE phenotype on postprandial triglycerides levels in young male with and without a familial history of myocardial infarction: The EARS II study. Atherosclerosis, 1997, 134, 85.	0.8	0
264	1.P.352 The Stanislas Cohort. A familial and longitudinal study for cardiovascular risks evaluation. Atherosclerosis, 1997, 134, 91.	0.8	0
265	Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. Journal of the Neurological Sciences, 1997, 145, 33-39.	0.6	54
266	3.P.128 Individual and familial determinants of autoantibodies against oxidized low density lipoprotein (oLAb). Atherosclerosis, 1997, 134, 225.	0.8	0
267	High Sensitivity of Laser-Induced Fluorescence Detection in Capillary Gel Electrophoresis for Accurate Apolipoprotein E Genotyping. BioTechniques, 1997, 22, 736-742.	1.8	9
268	Apolipoprotein E genotype $?4/?2$ in the STANISLAS Cohort Study - Dominance of the $?2$ allele $?$. Annals of Human Genetics, 1996 , 60 , $509-516$.	0.8	23
269	Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Clinica Chimica Acta, 1996, 253, 127-143.	1.1	10
270	Letter to the Editor: High-resolution separation of PCR product and gene diagnosis by capillary gel electrophoresis., 1996, 10, 48-50.		9

#	Article	IF	Citations
271	Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clinical Genetics, 1996, 50, 339-347.	2.0	26
272	Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Genetic Epidemiology, 1996, 13, 179-192.	1.3	0
273	Lipid and lipoprotein genetic variability: An important contribution from the French health Examination Centers. Clinical Biochemistry, 1995, 28, 31-38.	1.9	8
274	DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Atherosclerosis, 1995, 116, 221-234.	0.8	54
275	Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Atherosclerosis, 1995, 118, 23-34.	0.8	19
276	Sources of variability of human plasma apolipoprotein A-IV levels and relationships with lipid metabolism. Genetic Epidemiology, 1994, 11, 101-114.	1.3	11
277	Association of apolipoprotein E allele ϵ4 with lateâ€onset sporadic Alzheimer's disease. American Journal of Medical Genetics Part A, 1994, 54, 286-288.	2.4	43
278	The effect of variation in the apolipoprotein B gene on plasma lipid and apolipoprotein B levels I. A likelihoodâ€based approach to cladistic analysis. Annals of Human Genetics, 1994, 58, 35-64.	0.8	37
279	Apolipoprotein E-∈ A allele and Alzheimer's disease. Lancet, The, 1993, 342, 1308-1309.	13.7	51
280	The Role of Genetics in Defining Reference Values and Health Status. Methods of Information in Medicine, 1993, 32, 255-259.	1.2	4
281	Multivariate genetic analysis of high density lipoprotein particles. Atherosclerosis, 1992, 92, 219-227.	0.8	46
282	Signal peptide-length variation in human apolipoprotein B gene. Molecular characteristics and association with plasma glucose levels. Diabetes, 1991, 40, 1539-1544.	0.6	13
283	Familial resemblance of plasma apolipoprotein B: The Nancy study. Genetic Epidemiology, 1990, 7, 187-197.	1.3	16
284	Biological factors affecting concentrations of serum LpAI lipoprotein particles in serum, and determination of reference limits. Clinical Chemistry, 1990, 36, 677-680.	3.2	19
285	Two polymorphisms for amino acid substitutions in the APOA4 gene. Nucleic Acids Research, 1990, 18, 4966-4966.	14.5	38
286	Study of the sequence tagged site (STS) in the beginning of human apo A4 gene region. Nucleic Acids Research, 1990, 18, 5576-5576.	14.5	1
287	Two-dimensional electrophoresis of plasma proteins and high density lipoproteins during inflammation. Electrophoresis, 1989, 10, 781-784.	2.4	11
288	Systematic analysis of serum lipoproteins and apolipoproteins by a combined technique of micro two-dimensional electrophoresis. Electrophoresis, 1987, 8, 325-330.	2.4	35

#	Article	IF	CITATIONS
289	The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. American Journal of Medical Genetics Part A, 1987, 27, 567-582.	2.4	204
290	Immunochemical study of the plasma low and high density lipoproteins in Tangier disease. FEBS Letters, 1986, 201, 163-167.	2.8	8